Diagnostic and Prognostic Role of $^{18}$F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept

Francesco Fiz 1,*, Gianluca Bottoni 1, Giorgio Treglia 2,3,4, Pierpaolo Trimboli 4,5 and Arnoldo Piccardo 1,6

Since the discovery of the role of female hormones in breast cancer (BC) pathophysiology, in vivo detection of oestrogen receptor (ER) distribution has been one of the major goals of nuclear medicine and molecular imaging [1,2]. Hormone-blockade treatments represent, in fact, a safe and effective way to control ER-positive BC, even in the metastatic setting, and prevent recurrences [3–5]. Such an approach can be attempted in patients with evidence of ER on the clonal cell, which is estimated by biopsy or pathological examination of the primary tumour [6]. However, there is now ample evidence that ER expression might vary across disease sites, and there can be significant differences in this regard between primary tumour and distant metastases [7–9]. Since performing biopsies on remote disease localization might not always be feasible or even advisable, methods to obtain this information non-invasively have been sought after. The initial attempts in developing a molecular imaging tracer for scintigraphy imaging in the late 1970s were not successful, given the limited resolution of the method and the elevated background activity of some organs, such as liver [10,11]. However, some years later, the research group of Katzenellenbogen was able to develop a molecular imaging probe for PET devices, i.e., $^{18}$F-fluoroestradiol (FES), which was effectively the first radio-receptor positron-emitting tracer [12]. This tracer showed immediate promise; however, the related PET imaging method was then still in its infancy, and even later, the tracer landscape would continue to be dominated by fluorodeoxyglucose (FDG) for many years to come. It was only towards the end of the second decade of the 21st century that FES gained significant traction, leading to a marked increase of published research papers as well as its official approval, firstly in France (2016) and then in the United States of America (2020) [13].

The approval of FES-PET was grounded on its excellent capability of predicting the actual ER expression status on pathology; in a study by Chae and colleagues, among 37 patients with a positive FES-PET, all of them had oestrogen receptors on immunohistochemistry [14]. These data were recently confirmed by a larger, prospective trial, where FES-PET was able to predict the ER expression with very high sensitivity in the biopsied tumour lesions as well as in remote bone localizations [15]. In turn, the presence of ER is the only factor that can predict the effectiveness of endocrine therapy; tumour sites with poor or absent ER expression do not respond well to this approach [16,17]. Conversely, a widespread and intense FES positivity is linked with well-differentiated, ER-positive tumour forms, which have a significant chance to respond well to the endocrine treatment.

[References and further details on the study and its implications]
In this sense, FES-PET represents a theranostic approach, directing the patients toward the most suitable therapy, while avoiding the costs and the potential side effects of an inadequate one [18].

It must be highlighted that, understandably, there are some caveats and limitations to this approach. First, the diagnostic potential of the method might vary, since physiological background activity might affect the detectability of tumour lesions; this issue is particularly marked in the liver, which presents the highest density of oestrogen receptors [19]. However, bone is the principal metastatic site of ER+ BC, which has a lower tendency to colonize visceral organs when compared with other BC subtypes [20]. Some factors, such as body mass index and level of sex hormone-binding globulin, may have a mild-to-moderate effect on FES uptake, whereas other factors, such as the menopausal status, do not [21]. Secondly, even if the method is very sensitive in determining the ER expression, this parameter represents a necessary, yet not per se sufficient, condition for the success of the endocrine treatment [16]. In fact, triggering of the ER-dependent intracellular mechanisms in BC can occur despite a pharmacological endocrine blockade, via functional alteration of intracellular domains or crosstalk with other pathways [22,23]. Consequently, even in the case of a positive FES-PET, the real effectiveness of a first-line endocrine treatment could vary across patients. Finally, especially in the metastatic setting, different cellular clones, with varying degrees of biological aggressiveness, might co-exist in the same patients. Particularly, an aggressive disease is signalled by the disappearance of ER on the cell and increased proliferation rate; in such a setting, the switch towards FDG-PET or a dual tracer (FES/FDG) PET is advised [24]. The FDG-positive disease is linked with a poorer prognosis and tends to not respond to endocrine treatment; in the case of mixed FDG- and FES-positive disease, the FDG/FES ratio, i.e., the measure of how prevalent the less differentiated component is, represents an important factor for predicting disease progression and patients’ overall survival [25].

Besides the identification of the aggressive clonal component, FDG-PET has an excellent sensitivity at the patient level, which is comparable to the one afforded by FES-PET [26]. However, FES-PET has better lesion-based sensitivity, especially in the restaging setting [26].

In conclusion, considering available evidence-based data [26–28], FES-PET proved to be a valid diagnostic, prognostic, and theranostic approach, which, after many years of preparation, is ready to take the main stage of differentiated cancer identification and treatment.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Russo, J.; Russo, I.H. The role of estrogen in the initiation of breast cancer. J. Steroid Biochem. Mol. Biol. 2006, 102, 89–96. [CrossRef]
2. Katzenellenbogen, J.A. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[125I]iodo-estradiol (FES), a PET radiotracer for the estrogen receptor, a historical review. Nucl. Med. Biol. 2021, 92, 24–37. [CrossRef]
3. Drăganescu, M.; Carmocan, C. Hormone Therapy in Breast Cancer. Chirurgia 2017, 112, 413–417. [CrossRef] [PubMed]
4. Diaby, V.; Tawk, R.; Sanogo, V.; Xiao, H.; Montero, A.J. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res. Treat. 2015, 151, 27–40. [CrossRef] [PubMed]
5. Dalmau, E.; Armengol-Alonso, A.; Muñoz, M.; Segui-Palmer, M. Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. Breast 2014, 23, 710–720. [CrossRef] [PubMed]
6. Jensen, E.V.; Jordan, V.C. The Estrogen Receptor: A Model for Molecular Medicine. Clin. Cancer Res. 2003, 9, 1980–1989.
7. Walter, V.; Fischer, C.; Deutsch, T.M.; Ersing, C.; Nees, J.; Schütz, F.; Fremd, C.; Grischke, E.M.; Sinn, P.; Brucker, S.Y.; et al. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Res. Treat. 2020, 183, 137–144. [CrossRef]
8. Pusztai, L.; Viale, G.; Kelly, C.M.; Hudis, C.A. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010, 15, 1164–1168. [CrossRef]
9. Yeung, C.; Hilton, J.; Clemons, M.; Mazzarello, S.; Hutton, B.; Haggar, F.; Addison, C.L.; Kuchuk, I.; Zhu, X.; Gelmon, K.; et al. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review. Cancer Metastasis Rev. 2016, 35, 427–437. [CrossRef]
10. Hochberg, R.B.; Rosner, W. Interaction of 16 alpha-[125I]iodo-estradiol with estrogen receptor and other steroid-binding proteins. Proc. Natl. Acad. Sci. USA 1980, 77, 328–332. [CrossRef]
11. Katzenellenbogen, J.A. The development of gamma-emitting hormone analogs as imaging agents for receptor-positive tumors. *Prog. Clin. Biol. Res.* 1981, 75B, 313–327. [PubMed]

12. Kiesewetter, D.O.; Kilbourn, M.R.; Landvatter, S.W.; Heiman, D.F.; Katzenellenbogen, J.A.; Welch, M.J. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. *J. Nucl. Med.* 1984, 25, 1212–1221. [PubMed]

13. Pabst, K.M.; Decker, T.; Kersting, D.; Bartel, T.; Sraieb, M.; Herrmann, K.; Seifert, R. The Future Role of PET Imaging in Metastatic Breast Cancer. *Oncol. Res. Treat.* 2022, 45, 18–25. [CrossRef] [PubMed]

14. Chae, S.Y.; Ahn, S.H.; Kim, S.B.; Han, S.; Lee, S.H.; Oh, S.J.; Lee, S.J.; Kim, H.J.; Ko, B.S.; Lee, J.W.; et al. Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-estradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: A prospective cohort study. *Lancet Oncol.* 2019, 20, 546–555. [CrossRef]

15. van Geel, J.J.L.; Boers, J.; Elias, S.G.; Glaudemans, A.W.; de Vries, E.F.; Hospers, G.A.; van Kruchten, M.; Kuip, E.J.; Jager, A.; Menke-van der Houven, W.C.; et al. Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. *J. Clin. Oncol.* 2022, Jco2200400. [PubMed]

16. van Kruchten, M.; de Vries, E.G.E.; Brown, M.; de Vries, E.F.; Glaudemans, A.W.; Dierckx, R.A.; Schröder, C.P.; Hosper, G.A. PET imaging of oestrogen receptors in patients with breast cancer. *Lancet Oncol.* 2013, 14, e465–e475. [CrossRef] [PubMed]

17. van Kruchten, M.; Glaudemans, A.W.; de Vries, E.F.J.; Schroder, C.P.; de Vries, E.G.E.; Hosper, G.A.F. Positron emission tomography of tumour [18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. *Eur. J. Nucl. Med. Mol. Imaging* 2015, 42, 1674–1681. [CrossRef]

18. Choudhury, S.; Agrawal, A.; Pantvaidya, G.; Shah, S.; Purandare, N.; Puranik, A.; Rangarajan, V. Assessment of the Impact of 2015 American Thyroid Association guidelines in management of differentiated thyroid cancer patients. *Eur. J. Nucl. Med. Mol. Imaging* 2020, 47, 547–553. [CrossRef]

19. Beauregard, J.M.; Croteau, E.; Ahmed, N.; van Lier, J.E.; Bénard, F. Assessment of human biodistribution and dosimetry of 4-fluoro-1beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT. *J. Nucl. Med.* 2009, 50, 100–107. [CrossRef]

20. Lee, S.J.; Park, S.; Ahn, H.K.; Yi, J.H.; Cho, E.Y.; Sun, J.M.; Lee, J.E.; Nam, S.J.; Yang, J.H.; Park, Y.H.; et al. Implications of bone-only metastases in breast cancer: Favorable preference with excellent outcomes of hormone receptor positive breast cancer. *Cancer Res. Treat.* 2011, 43, 89–95. [CrossRef]

21. Peterson, L.M.; Kurland, B.F.; Link, J.M.; Schubert, E.K.; Stekhova, S.; Linden, H.M.; Mankoff, D.A. Factors influencing the uptake of 18F-fluoroeastriol in patients with estrogen receptor positive breast cancer. *Nucl. Med. Biol.* 2011, 38, 969–978. [CrossRef] [PubMed]

22. Arnesen, S.; Blanchard, Z.; Williams, M.M.; Berrett, K.C.; Li, Z.; Oesterreich, S.; Richer, J.K.; Gertz, J. Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects. *Cancer Res.* 2021, 81, 539–551. [CrossRef]

23. AlFakeeh, A.; Brezden-Masley, C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. *Curr. Oncol.* 2018, 25, 18–27. [CrossRef] [PubMed]

24. Paydary, K.; Seraj, S.M.; Zadeh, M.Z.; Emanazadehfard, S.; Shamchi, S.P.; Gholami, S.; Werner, T.J.; Alavi, A. The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. *Mol. Imaging Biol.* 2019, 21, 1–10. [CrossRef] [PubMed]

25. Bottoni, G.; Piccardo, A.; Fiz, F.; Siri, G.; Matteucci, F.; Rocca, A.; Nanni, O.; Monti, M.; Brain, E.; Alberini, J.L.; et al. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroeastriol PET/CT and [18F]Fluorodeoxyglucose PET/CT. *Eur. J. Radiol.* 2021, 141, 109821. [CrossRef]

26. Piccardo, A.; Fiz, F.; Treglia, G.; Bottoni, G.; Trimboli, P. Head-to-Head Comparison between 18F-FES PET/CT and 18F-FDG PET/CT in Oestrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-Analysis. *J. Clin. Med.* 2022, 11, 1919. [CrossRef]

27. Kurland, B.F.; Wiggins, J.R.; Coche, A.; Fontan, C.; Bouvet, Y.; Webner, P.; Divgi, C.; Linden, H.M. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Safety of Integration into Clinical Applications. *Oncologist* 2020, 25, 835–844. [CrossRef]

28. Mo, J.A. Safety and Effectiveness of F-18 Fluoroestradiol Positron Emission Tomography/Computed Tomography: A Systematic Review and Meta-analysis. *J. Korean Med. Sci.* 2021, 36, e271. [CrossRef]